Synergistic Combination of Luteolin and Asiatic Acid on Cervical Cancer In Vitro and In Vivo

Cervical Cancer is an important issue globally because it is the second most common gynecological malignant tumor and conventional treatment effects have been shown to be limited. Lut and AsA are plant-derived natural flavonoid and triterpenoid products that have exhibited Anticancer activities and can modulate various signaling pathways. Thus, the aim of the present study was to evaluate whether Lut combined with AsA could enhance the Anticancer effect to inhibit cervical Cancer cell proliferation and examine the underlying molecular mechanisms in vitro and in vivo. The results of a CCK-8 assay showed that Lut combined with AsA more effectively inhibited the proliferation of CaSki and HeLa cells than Lut or AsA treatment alone. Lut combined with AsA caused Apoptosis induction and sub-G1-phase arrest in CaSki and HeLa cells, as confirmed by flow cytometry, mitoROS analysis, antioxidant activity measurement and western blot assay. In addition, Lut combined with AsA significantly inhibited the cell migration ability of CaSki and HeLa cells in a wound-healing assay. Furthermore, Lut combined with AsA induced Apoptosis and inhibited migration through downregulated PI3K/Akt (PI3K, Akt and p70S6K), JNK/p38 MAPK and FAK (Integrin β1, paxillin and FAK) signaling and upregulated ERK signaling. In an in vivo study, Lut combined with AsA markedly inhibited cervical Cancer cell-derived xenograft tumor growth. Collectively, the present study showed that Lut combined with AsA may be used as an Anticancer agent to improve the prognosis of cervical Cancer. Indeed, with additional research to develop standardized dosages, Lut and AsA combination therapy could also be applied in clinical medicine.

JNK/p38/ERK; PI3K/AKT/p70S6K; asiatic acid; cervical cancer; integrin β1/paxillin/FAK; luteolin.